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Summary 16 
Nitrous oxide (N2O) is frequently used for short anaesthesia/analgesia in children undergoing painful 17 
or repetitive procedures1. Children with acute lymphoblastic leukaemia (ALL) require repeated lumbar 18 
punctures with direct instillation of intrathecal chemotherapy, usually the anti-folate agent 19 
Methotrexate, during their treatment. These procedures are frequently performed under anaesthesia. 20 
Concerns have been intermittently raised about a drug-interaction between methotrexate and N2O 21 
that may potentiate the undesirable side effects of methotrexate, including neurotoxicity. However, the 22 
clinical evidence consists mainly of isolated case reports leading to a lack of consensus amongst 23 
paediatric anaesthetists about the relative risk-benefits of using N2O in children with ALL. In this 24 
article, we review the biochemical basis and scientific observations that suggest a significant 25 
interaction between N2O and methotrexate due to their dual inhibition of the key enzyme methionine 26 
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synthase. The possible role of this interaction in potentiating neurotoxicity in children with cancer is 27 
discussed, and arguments and counter-arguments about the clinical significance of this largely 28 
theoretical relationship are explored. Following comprehensive review of all the available data we 29 
make the case for the circumstantial evidence being sufficiently compelling to prompt a review of 30 
practice by paediatric anaesthetists and call for a precautionary approach by avoiding the use of N2O 31 
in children receiving concurrent methotrexate. 32 
Introduction 33 
N2O is still a widely used anaesthetic and is often used for short anaesthesia/analgesia in patients 34 
undergoing painful or uncomfortable procedures such as dressing changes, lumbar punctures and 35 
intrathecal chemotherapy. Concern has been intermittently raised about N2O toxicity. In Denmark 36 
during the 1950s several patients with tetanus were given N2O for a period of days to facilitate 37 
ventilation and suffered bone marrow toxicity 2.  Haematological toxicity of prolonged N2O therapy has 38 
since been well documented, but a number of questions remain regarding neurotoxic effects, 39 
amplified toxicity when co-administered with other drugs, and the impact of short, but repeated, bouts 40 
of exposure. 41 
It is increasingly appreciated that children receiving chemotherapy for acute lymphoblastic leukaemia 42 
(ALL) may experience adverse neurological and neurocognitive outcomes, both acutely and long-43 
term, with methotrexate implicated as the main causative agent3,4. Neurotoxicity takes many forms. 44 
Some patients experience devastating acute neurological side effects with highly varied clinical 45 
presentations, including stroke-like syndrome, seizures and paralysis. Others have evidence of 46 
subclinical white matter changes (leukoencephalopathy) on MRI scanning5 – a finding that has been 47 
linked to long-term adverse neurocognitive and neurobehavioral outcomes6. Finally, up to 40% of 48 
long-term survivors display some measurable defects in neurocognition, the commonest being 49 
impairments in processing speed, memory and executive function7. These deficits are persistent, 50 
even decades after treatment, and have been shown to have negative impacts on educational 51 
attainment and employment8. 52 
The risk factors for these adverse neurological outcomes are not clearly established and some clinical 53 
features of neurotoxicity suggest that environmental factors may be important determinants of risk9.  54 
Two recent case reports highlighted severe neurotoxicity in children undergoing intrathecal 55 
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methotrexate treatment for ALL with a drug interaction between N2O and methotrexate being 56 
postulated as a possible contributing factor9,10. Despite this, N2O is still a popular choice of 57 
anaesthetic agent for these children, with a recent paper even discussing the potential benefits of its 58 
use in children with leukaemia11. 59 
In this article, we review the biochemical basis and scientific observations that suggest a significant 60 
interaction between N2O and methotrexate and discuss the possible role of this interaction in 61 
potentiating acute and chronic neurotoxicity in vulnerable patient groups.  We make the case for the 62 
circumstantial evidence being sufficiently compelling to prompt a review of practice by paediatric 63 
anaesthetists and call for a precautionary approach by avoiding the use of N2O in children receiving 64 
concurrent methotrexate. 65 
N2O mechanism of action and use in anaesthesia   66 
N2O is one of the oldest anaesthetic drugs, it was first synthesised by Joseph Priestly in 1772 and 67 
widely experimented upon by Humphry Davy who recognised its analgesic properties in the early 19th 68 
century. Its popularity in anaesthesia is credited to Horace Wells, a dentist practicing in the United 69 
States of America who began using N2O clinically in 184412. Today N2O is supplied as a pressurised 70 
liquid in cylinders and used as a gas as it vaporises upon reduction of pressure during administration. 71 
It may be supplied as pure N2O or in a cylinder with 50/50 mixture of Oxygen and N2O (Entonox). 72 
Despite the advent of many newer anaesthetic agents, N2O remains extremely popular with 73 
anaesthetists today and is used in over 20% of anaesthetics13-15.   The potentially beneficial properties 74 
of N2O during anaesthesia include: 75 
i) The second gas effect: As N2O is rapidly absorbed from the alveolus, it has the effect of increasing 76 
the relative concentration of other gases and therefore their partial pressure and their own uptake is 77 
increased. This creates more rapid induction to the desired state of anaesthesia. Similarly, when N2O 78 
is ceased it will diffuse rapidly out of circulation, expanding the alveolus and create a favourable 79 
concentration gradient for the rapid exhalation of volatile agents and speeding up recovery from 80 
anaesthesia16.   81 
ii) Contribution to the depth of anaesthesia; N2O has a stable profile concerning the cardiovascular 82 
system in contrast to some volatile agents, so the incorporation of N2O in an anaesthetic allows 83 
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reduction in the dose of volatile agent and potentially a more stable patient. A large audit on 84 
unintentional awareness also pointed towards a role for N2O in the provision of adequate depth of 85 
anaesthesia during Caesarean Section17,18  86 
iii) At atmospheric pressure N2O cannot provide surgical anaesthesia and the ceiling effect on the 87 
CNS at a level of ‘sedation’ have proven a useful property for physicians and other health 88 
professionals not wishing to inadvertently administer deeper planes of anaesthesia with their 89 
attendant risks of cardiorespiratory depression leading to the requirement for pre-procedural 90 
starvation along with a higher degree of both medical supervision and monitoring.   91 
iv) Analgesia; N2O promotes release of endogenous opiates in the central nervous system, however 92 
its principal analgesic action seems to be effected via N-methyl-D-aspartate (NMDA) inhibition 19 93 
unfortunately its effects on prevention of chronic pain are confined to patients with a variant 94 
methylenetetrahydrofolate reductase (MTHFR) gene 20  95 
Historically, N2O has earned a deserved role in as an agent for brief procedural sedation in children 96 
due to the combined properties of physiological stability, rapid dose titration, administration by 97 
inhalation, analgesia and especially, low potential for acute over-dose. None of the alternative 98 
sedative agents be they opiates, benzodiazepines or intravenous anaesthetic agents such as 99 
ketamine or propofol can match this and although large comparative outcome studies are lacking21, 100 
expansion of other agents into the widespread role for sedation occupied by N2O has not occurred.  101 
Studies do exist confirming the acceptability and efficiency and extremely low acute complication rate 102 
of Nitrous administration in preference to other sedation agents for lumbar puncture11,22,23. These are 103 
important to recognise as counterbalancing this, it does have a number of undesirable properties, for 104 
example: 105 
i)  It is a greenhouse gas. 106 
ii) It may reduce fertility in healthcare workers24 107 
iii) It causes trapped gas in the gastrointestinal tract to expand and is implicated in postoperative 108 
nausea and vomiting. 109 
iv) It can cause megaloblastic anaemia with prolonged or repeated use 25,26. 110 
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iv) And most importantly for this article, it has been reported to cause severe neurological injury, in the 111 
form of subacute combined degeneration of the cord in patients with occult vitamin B12 deficiency27,28. 112 
The British National Formulary lists the side effects of N2O as depression of white blood cell 113 
formation, hypoxia and neurological toxic effects, linking this to ‘interference with the action of vitamin 114 
B12’ and noting that ‘neurological side effects can occur without preceding, overt haematological 115 
changes’ 29. The links between methotrexate, vitamin B12, N2O, and haematological and neurological 116 
toxicity are summarised in figure 1. 117 
Methotrexate use in leukaemia 118 
Methotrexate is a common component of paediatric and adult acute lymphoblastic leukaemia and 119 
lymphoma treatment regimens. It is administered intravenously, orally and intrathecally, the latter 120 
largely replacing cranial and spinal radiotherapy in the 1990’s as a method to eradicate leukaemic 121 
cells from the CNS, reducing the risk of relapse. However, both acute and chronic neurological side 122 
effects are reported following methotrexate use, including seizures, leukoencephalopathy and stroke-123 
like syndrome 5,30-32. Additionally, long-term neurotoxicity manifesting as neurocognitive impairment is 124 
an emerging concern affecting a substantial number of childhood leukaemia survivors 33-35. 125 
Briefly, methotrexate works by inhibiting the enzyme dihydrofolate reductase (DHFR), stopping the 126 
cell from processing folate into tetrahydrofolate (THF) required for DNA synthesis, eventually leading 127 
to cell death. As with many older chemotherapy agents, this effect is not cancer-cell specific and 128 
patients on methotrexate experience drug toxicity, particularly in rapidly-dividing cells such as those of 129 
the gut and bone marrow with mucositis and low blood counts being commonly reported side effects. 130 
This is a result of inhibition of purine and pyrimidine synthesis – the building blocks for DNA (fig 1). In 131 
paediatric leukaemia patients, folate rescue in the form of leucovorin is typically given 24-42 hours 132 
after intravenous high-dose methotrexate therapy in an attempt to limit toxicity in normal tissues, 133 
whilst still allowing time for the drug to function on leukaemia cells. 134 
 135 
Not all patients experience methotrexate neurotoxicity and the range of clinical manifestations is vast 136 
and complex, meaning it has been difficult to make progress on identifying risk-factors that predispose 137 
to these distressing and sometimes disabling side-effects. Although the intensity of methotrexate 138 
therapy36 and various pharmacokinetic parameters5 are implicated in some studies, there remains 139 
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considerable variation in occurrence of neurotoxicity between patients despite similar drug exposure. 140 
Paediatric leukaemia treatment regimens involve multi-agent chemotherapy plus additional drugs to 141 
manage treatment-related side effects. We hypothesized in a previous paper that interactions with 142 
other drugs and/or low nutrient levels might contribute towards explaining the variability in 143 
susceptibility to neurotoxicity.  Some drugs have a direct interaction resulting in increased 144 
methotrexate drug levels (e.g. fluoroquinolone antibiotics). A more insidious cause could be the 145 
interference with the same metabolic pathways as methotrexate and, in particular, additive effects on 146 
methionine synthase activity.  147 
The mechanisms of both acute and chronic methotrexate neurotoxicity are incompletely understood 148 
but experimental and clinical evidence points to two main pathways. Firstly, by activating microglia 149 
resulting in impaired oligodendrocyte maturation and myelination37, and secondly reduced synthesis 150 
of methionine from its precursor homocysteine – a reaction catalysed by the key enzyme methionine 151 
synthase. The latter results in excess homocysteine and a reduction in methionine both of which may 152 
be neurotoxic as shown in figure 1. Homocysteine excess has been shown in preclinical animal 153 
models to result in cognitive impairment via activation of the NMDA receptor38 and NMDA blockade is 154 
able to reverse these cognitive defects39. This is supported by human studies confirming a link 155 
between elevated homocysteine levels and seizures (acute neurotoxicity) (29) as well as elevated 156 
myelin basic protein in CSF (suggesting demyelination and chronic neurotoxicity)  40,41.  The 157 
accompanying reduction in methionine levels may also results in downstream effects on myelin 158 
sheath homeostasis and regulation of lipid production and thus potentially synergizes with the direct 159 
effect on oligodendrocyte myelination. Thus, reduced conversion of homocysteine to methionine 160 
appears to be a key factor underlying methotrexate-induced neurotoxicity. It is critical to note that the 161 
enzyme catalyzing this reaction– methionine synthase is directly inhibited by N2O, and N2O exposure 162 
has been shown to significantly increase plasma homocysteine concentrations after surgery42,43. 163 
Thus, methotrexate and N2O directly impinge on the same chemical reaction leading to the potential 164 
for enhanced toxicity even with low doses or short exposures. The principle of enhanced neurotoxicity 165 
by a double hit on this pathway is illustrated by a case report in the New England Journal of Medicine 166 
(NEJM) describing the neurological deterioration and death of a child anaesthetised twice with N2O 167 
prior to a diagnosis of methyltetrahydrofolate reductase deficiency44. 168 
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Neurotoxicity may be further compounded by a second interaction with low vitamin B12 levels45. 169 
Methionine synthase requires vitamin B12 as an essential co-factor. N2O prevents formation of active 170 
(oxidized) B12 and this results in irreversible inactivation of methionine synthase (Figure 1). 171 
Restoration of activity requires new synthesis of the enzyme.  In the presence of B12 deficiency, any 172 
impact of methotrexate and N2O on methionine synthase activity is likely to be significantly amplified. 173 
One small paediatric study showed significant correlation between plasma homocysteine rises in 174 
response to N2O and pre-operative vitamin B12 levels46. Low B12 levels could be dietary or due to 175 
other drugs such as proton pump inhibitors, which prevent absorption of vitamin B12 via blocking the 176 
production of intrinsic factor 9. Paediatric leukaemia patients may have poor nutritional status 177 
secondary to drug side effects such as enteropathy, mucositis and anorexia. Although B12 levels are 178 
not routinely measured in most centres, one small study, conducted in India, documented low B12 179 
levels in 25/80 (31%) of children completing ALL therapy 47.  180 
Much of the heterogeneity in occurrence of neurotoxicity in children given the same intrathecal 181 
methotrexate regime could theoretically stem from these additional factors such as interacting drugs, 182 
low B12 levels and other nutritional deficiencies. Moreover, these factors could significantly influence 183 
the sensitivity to N2O, which would have additive effects by inactivation of vitamin B12. A dose of N2O 184 
that was harmless to a B12 replete individual on a low dose of oral methotrexate may have 185 
significantly different effects in the presence of directly injected intrathecal methotrexate in a patient 186 
with already borderline or low B12 levels. 187 
Evidence of a methotrexate/ N2O interaction in patients 188 
Of course, the evidence presented above is largely theoretical and/or circumstantial. The best direct 189 
evidence for N2O potentiating methotrexate toxicity comes from studies in breast cancer. Two studies 190 
involving large numbers of breast cancer patients (368 and 2466, respectively), most of whom 191 
received N2O anaesthesia concluded that unpredictable toxic effects of methotrexate such as low 192 
blood counts and mucositis were likely due to the combined effect of methotrexate and N2O on folate 193 
metabolism, which was at least partially rescued by the administration of leucovorin 48,49. 194 
Unfortunately, these studies did not evaluate acute or chronic neurological outcomes. However, two 195 
case studies have also been published suggesting a link between neurotoxicity and concomitant N2O 196 
and methotrexate use9,10.  197 
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Briefly, the first case report involved a 7-year old patient who experienced severe neurotoxicity 198 
following her third intrathecal methotrexate dose10. Her first LP had been performed under general 199 
anaesthesia but the second and third had used N2O/oxygen gas mix (50:50). She presented with 200 
dysarthria followed by a decreasing level of consciousness (Glasgow coma scale 4). No infective 201 
cause was found and MRI showed leukoencephalopathy with signs of vasogenic oedema. The most 202 
likely cause was methotrexate neurotoxicity possibly potentiated by the concomitant use of N2O. The 203 
patient made a slow recovery over several months and was not exposed to further intrathecal 204 
methotrexate. 205 
The second case report involved a 12-year old patient who experienced seizures, limb weakness and 206 
agitation after her fifth dose of intrathecal methotrexate administered under N2O anaesthesia9. Her 207 
serum vitamin B12 levels were measured three weeks after her last intrathecal MTX and found to be 208 
below the normal range at 154ng/L (normal range 200-1100ng/L) She made a clinical recovery over 2 209 
weeks but was left with some residual left upper limb weakness 9.  210 
Also of interest, is the perceived lower incidence of neurotoxic effects in adult patients with ALL 211 
receiving intrathecal methotrexate treatment. Much of this is anecdotal with little direct supporting 212 
evidence in the literature.  The best comparison comes from the NOPHO ALL2008 trial, which treated 213 
patients up to age 45. Seizures were reported in 6.1% of 10-17 year olds but only 2.4% of 18-45 year 214 
olds this did not reach statistical significance 50. Notably, adult patients usually undergo lumbar 215 
puncture without sedation or general anaesthetic so are unlikely to be exposed to the combination of 216 
N2O plus intrathecal methotrexate. This evidence is highly circumstantial but is a possible avenue for  217 
further investigation. 218 
Although these case reports and clinical observations are clearly not conclusive, we believe they may 219 
be indicative of a larger problem, which requires further study and immediately warrants more caution 220 
in the field. 221 
Supporting pre-clinical evidence 222 
Although the clinical data above are limited, there are also a number of supporting observations using 223 
in vitro and in vivo models. Interestingly, N2O has been historically touted as a possible treatment for 224 
cancers and a potentiation agent for methotrexate. N2O was first reported as a possible treatment for 225 
CML in 1959 51. Tests exposing leukaemia cell lines to N2O showed a reduction in growth via impaired 226 
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5-methyl-THF metabolism. Additionally, N2O exposure of the leukaemic U937 cell line and primary 227 
leukaemia samples revealed a disruption of nucleotide synthesis, which was accentuated by 228 
concomitant exposure to methotrexate 52.  229 
A number of animal studies have explored the link between N2O and methotrexate. One such study 230 
exposed rats to N2O for 12-48 hours before dosing with a single intraperitoneal injection of 10-231 
80mg/kg body weight methotrexate (equivalent to routinely used doses in paediatric leukaemia 232 
treatment)53. The 50% lethal dose for methotrexate was reduced six-fold from 60mg/kg to 10mg/kg in 233 
rats pre-exposed to a mixture of 5-50% N2O for 48 hours and some increase in lethality was observed 234 
with 12-hour exposures. Combining methotrexate and N2O also showed increase anti-leukaemic 235 
effect in rat myeloid leukaemia models 54. Separate studies using 12-hour exposures showed that 236 
methionine synthase activity is completely suppressed and the conversion of methyl-THF to other 237 
folate variants needed for purine and thymidylate synthesis is also impacted 55,56. A 4-hour exposure 238 
of N2O was also shown to reduce 90% of hepatic methionine synthase activity, with a 50% reduction 239 
in tetrahydrofolate. In this model, it took 48 hours exposure to normal air for the methionine synthase 240 
levels to return to normal 57. 241 
It is difficult to ascertain how these long exposures in rats relate to the normally relatively short 242 
exposures experienced by children receiving methotrexate therapy for childhood leukaemia treatment. 243 
However, Entonox is 50% N2O, representing the highest volume used in this study, with other work 58, 244 
showing that exposure of a 2% mixture for 15 hours resulted in a 30% inhibition of methionine 245 
synthase in rat liver. Most strikingly however was that 15 minutes of exposure to 50% N2O caused a 246 
55% reduction in methionine synthase activity in the liver, with a 1-hour exposure reducing methionine 247 
synthase activity to just 30% of controls. These levels of exposure are clinically relevant, with most 248 
children undergoing short durations of anaesthesia in the range 10-30 minutes for lumbar puncture 249 
administration of methotrexate. Although methionine synthase activity has been measured in livers of 250 
these rats, it is reasonable to hypothesise that neural tissue may be similarly affected, especially 251 
since in patients the methotrexate is injected directly into the central nervous system. 252 
Current state of play 253 
As can be seen from the discussion above there is no single definitive piece of evidence that proves a 254 
causal link between N2O and enhanced methotrexate neurotoxicity. This lack of published evidence 255 
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has led to some counter arguments that short exposures to N2O in children are unlikely to be harmful. 256 
In addition, there are some perceived advantages in terms of flexibility and ease11 over alternative 257 
approaches. Together this has resulted in continued use of this agent and a lack of general 258 
acceptance in the anaesthetic community that an interaction with methotrexate is an important contra-259 
indication to its use. We would like to advance the following arguments in support of our case: 260 
1. The published clinical studies showing that prolonged exposure is needed to cause neurological 261 
adverse events in the context of low B12 did not include patients receiving methotrexate. Conversely, 262 
those investigating methotrexate interactions did not measure B12 levels. In addition, in the breast 263 
cancer study methotrexate was given IV rather than intrathecally, presumably resulting in significantly 264 
lower methotrexate exposure in neuronal cells. Patients with ALL are receiving direct instillation of 265 
intrathecal methotrexate and have many reasons to be B12 deficient– this “double or even triple 266 
whammy” effect may cause neurotoxicity even after brief exposures in paediatric leukaemic patients.  267 
2. The lack of large-scale reporting of neurological adverse drug interactions to regulatory authorities 268 
does not necessarily mean that no interaction exists for the following reasons: 269 
 i) Neurotoxicity can be subtle and manifest many months or years after initial exposure, making 270 
establishment of a causal link problematic. 271 
 ii) Anaesthesia is only one part of a multi-agent exposure and many haematologists will be unaware 272 
of the anaesthetic agent used – the lack of prescribing of anaesthetic agents on drug charts means 273 
they are frequently omitted from lists of concomitant therapy on serious adverse event reports, which 274 
are part of mandatory clinical trial reporting. Thus, the opportunity to establish a causal link is lost.   275 
iii) The combination of intravenous induction agents plus N2O maintenance may well reduce overt 276 
neurotoxicity events such as seizures due to the anticonvulsant properties of many induction agents – 277 
this may give anaesthetists a false sense of security that neurotoxicity is an extremely rare event, 278 
whilst subclinical leukoencephalopathy with resultant effects on long-term neurocognitive outcomes 279 
could still be occurring. 280 
Ways to test these arguments are discussed below. In the meantime, we contend that the weight of 281 
evidence presented above should lead to implementation of the precautionary principle i.e. ”when an 282 
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activity raises threats of harm to human health or the environment, precautionary measures should be 283 
taken even if some cause and effect relationships are not fully established scientifically" 59.  284 
Future research directions 285 
A recent single-institution study has highlighted potential neurocognitive adverse effects of repeated 286 
propofol and volatile anaesthetic exposure during childhood cancer therapy60. This institution did not 287 
use N2O for sedation/anaesthesia during this period (corresponding author personal communication), 288 
and therefore does not provide any evidence for or against our arguments above. However, it does 289 
raise the possibility that some treatment centres may consider switching to N2O in place of propofol or 290 
volatile based anaesthesia. This makes the need for more research into adverse effects of N2O more 291 
pressing. Definitive proof of a causal role for N2O in enhanced methotrexate neurotoxicity would 292 
require a randomised trial of neurological outcomes following use of N2O versus alternative 293 
anaesthetic agents. However, given the weight of evidence suggesting potential interactions, and no 294 
convincing advantage for N2O use, a prospective study such as this would be likely to be rejected by 295 
Ethical review boards. A more feasible alternative is to retrospectively collect more detailed clinical 296 
and drug exposure data on patients experiencing acute and chronic neurotoxicity. Data on acute 297 
neurotoxic adverse events  is currently being collected by the iBFM/Ponte di Legno neurotoxicity 298 
working party3. This data will enable identification of particular patient groups or countries with high or 299 
low rates of neurotoxicity and may enable subsequent cohort studies comparing rates of acute 300 
neurotoxicity in patients with and without N2O exposure. To address the risk of chronic neurotoxicity 301 
collection of anaesthetic data on patients that are already participating in long-term neurocognitive 302 
outcome studies could be performed. It is also important to establish the prevalence of vitamin B12 303 
deficiency in patients undergoing leukaemia therapy, although retrospectively linking this to N2O 304 
exposure and neurocognitive outcomes will be challenging. The next best approach would be animal 305 
studies to investigate any additive effects of N2O anaesthesia plus methotrexate on cognitive tests or 306 
brain histology. These should be conducted as a matter of priority. Finally, innovations in cerebral 307 
organoid technology provide an excellent opportunity to studying the effect of methotrexate on white 308 
matter volume and structure as well as the relative quantities of various myelin proteins. Such models 309 
could then test whether increased toxicity is seen in the context of B12 restriction or reduced 310 
methionine synthase activity. A recent publication details a very plausible mechanism for long-term, 311 
methotrexate-induced cognitive difficulties, concluding that is likely due to tri-glial dysregulation 312 
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caused by activated microglia 37. Although this paper did not specifically look at acute side-effects of 313 
methotrexate exposure as in cases of stroke-like-syndrome, the strength of these findings warrant the 314 
monitoring of microglial activation in any future studies, including investigations on whether N2O has 315 
any effect on these processes. 316 
 317 
Conclusion 318 
Overall, the basic science evidence for a significant interaction between N2O and methotrexate is 319 
compelling. Direct proof of a causal link to enhanced neurotoxicity in patients is lacking, but 320 
prospective clinical studies to examine this are likely to be deemed unethical. In our expert opinion, 321 
and employing use of the precautionary principle, we support the statement that “N2O should not be 322 
used in acute lymphoblastic leukaemia patients receiving methotrexate”. Further retrospective cohort 323 
studies and preclinical studies should ensure anaesthetic, haemato-oncological and pharmaceutical 324 
input, in order to enhance the evidence base. However, since suitable alternatives exist, it seems 325 
sensible and prudent to call for a review of practice and at the very minimum a high level of clinical 326 
awareness and pharmacovigilance in patients on oral methotrexate receiving N2O.  327 
Disclosures 328 
This work was supported by the Glasgow Children’s Hospital Charity (PSG/2016/11) (C.H), Children 329 
with Cancer UK (14-170) (C.H) and the JGW Patterson Foundation, Newcastle upon Tyne, UK, (V.F). 330 
The authors have no conflicts of interest to declare. 331 
References 332 
1. Annequin D, Carbajal R, Chauvin P, Gall O, Tourniaire B, Murat I. Fixed 50% nitrous oxide 333 
oxygen mixture for painful procedures: A French survey. Pediatrics. 2000;105(4):E47. 334 
2. Lassen HC, Henriksen E, Neukirch F, Kristensen HS. Treatment of tetanus; severe bone-335 
marrow depression after prolonged nitrous-oxide anaesthesia. Lancet. 1956;270(6922):527-336 
530. 337 
3. Schmiegelow K, Attarbaschi A, Barzilai S, et al. Consensus definitions of 14 severe acute toxic 338 
effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. The Lancet 339 
Oncology. 2016;17(6):e231-e239. 340 
4. Halsey C, Buck G, Richards S, Vargha-Khadem F, Hill F, Gibson B. The impact of therapy for 341 
childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-342 
stratified randomized central nervous system treatment trial MRC UKALL XI. Journal of 343 
hematology & oncology. 2011;4:42. 344 
13 
 
5. Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and 345 
leukoencephalopathy in childhood acute lymphoblastic leukemia. Journal of clinical oncology 346 
: official journal of the American Society of Clinical Oncology. 2014;32(9):949-959. 347 
6. Cheung YT, Sabin ND, Reddick WE, et al. Leukoencephalopathy and long-term 348 
neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood 349 
acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. The 350 
Lancet Haematology. 2016;3(10):e456-e466. 351 
7. Cheung YT, Krull KR. Neurocognitive outcomes in long-term survivors of childhood acute 352 
lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review. 353 
Neuroscience and biobehavioral reviews. 2015;53:108-120. 354 
8. Krull KR, Brinkman TM, Li C, et al. Neurocognitive outcomes decades after treatment for 355 
childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. 356 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 357 
2013;31(35):4407-4415. 358 
9. Forster VJ, van Delft FW, Baird SF, Mair S, Skinner R, Halsey C. Drug interactions may be 359 
important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia 360 
patients. Cancer chemotherapy and pharmacology. 2016;78(5):1093-1096. 361 
10. Lobel U, Trah J, Escherich G. Severe neurotoxicity following intrathecal methotrexate with 362 
nitrous oxide sedation in a child with acute lymphoblastic leukemia. Pediatric blood & 363 
cancer. 2015;62(3):539-541. 364 
11. Livingston M, Lawell M, McAllister N. Successful use of nitrous oxide during lumbar 365 
punctures: A call for nitrous oxide in pediatric oncology clinics. Pediatric blood & cancer. 366 
2017;64(11). 367 
12. Haridas RP. Horace wells' demonstration of nitrous oxide in Boston. Anesthesiology. 368 
2013;119(5):1014-1022. 369 
13. Henderson KA, Raj N, Hall JE. The use of nitrous oxide in anaesthetic practice: a 370 
questionnaire survey. Anaesthesia. 2002;57(12):1155-1158. 371 
14. McKay RE. Nitrous oxide and cardiovascular outcome: perspective from the POISE trial. 372 
Anesth Analg. 2013;116(5):962-965. 373 
15. Buhre W, Disma N, Hendrickx J, et al. European Society of Anaesthesiology Task Force on 374 
Nitrous Oxide: a narrative review of its role in clinical practice. Br J Anaesth. 375 
2019;122(5):587-604. 376 
16. Peyton PJ, Chao I, Weinberg L, Robinson GJ, Thompson BR. Nitrous oxide diffusion and the 377 
second gas effect on emergence from anesthesia. Anesthesiology. 2011;114(3):596-602. 378 
17. Pandit JJ, Andrade J, Bogod DG, et al. 5th National Audit Project (NAP5) on accidental 379 
awareness during general anaesthesia: summary of main findings and risk factors. Br J 380 
Anaesth. 2014;113(4):549-559. 381 
18. TM PJC. AAGA in obstetric anaesthesia. National Audit Project 5. 2014:Recommendation 382 
16.12:c. https://www.nationalauditprojects.org.uk/NAP5report?newsid=1187#pt  383 
19. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an 384 
NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4(4):460-463. 385 
20. Chan MT, Peyton PJ, Myles PS, et al. Chronic postsurgical pain in the Evaluation of Nitrous 386 
Oxide in the Gas Mixture for Anaesthesia (ENIGMA)-II trial. Br J Anaesth. 2016;117(6):801-387 
811. 388 
21. Mason KP. Challenges in paediatric procedural sedation: political, economic, and clinical 389 
aspects. Br J Anaesth. 2014;113 Suppl 2:ii48-62. 390 
22. Hargens L SK, Moertel C, Moore C, Slomiany D, and Messinger Y. The Use of Nitrous Oxide To 391 
Treat Pain of Lumbar Punctures in Ambulatory Pediatric Leukemia and Lymphoma Patients. 392 
Blood. 2006;108(11):3306. 393 
14 
 
23. Liu Q, Chai XM, Zhang JJ, et al. A Fixed Nitrous Oxide and Oxygen Mixture for Analgesia in 394 
Children With Leukemia With Lumbar Puncture-induced Pain: A Randomized, Double-blind 395 
Controlled Trial. J Pain Symptom Manage. 2019;57(6):1043-1050. 396 
24. Rowland AS, Baird DD, Weinberg CR, Shore DL, Shy CM, Wilcox AJ. Reduced fertility among 397 
women employed as dental assistants exposed to high levels of nitrous oxide. The New 398 
England journal of medicine. 1992;327(14):993-997. 399 
25. Amess JA, Burman JF, Rees GM, Nancekievill DG, Mollin DL. Megaloblastic haemopoiesis in 400 
patients receiving nitrous oxide. Lancet. 1978;2(8085):339-342. 401 
26. Schilling RF. Is nitrous oxide a dangerous anesthetic for vitamin B12-deficient subjects? 402 
Jama. 1986;255(12):1605-1606. 403 
27. Patel KK, Mejia Munne JC, Gunness VRN, et al. Subacute combined degeneration of the 404 
spinal cord following nitrous oxide anesthesia: A systematic review of cases. Clin Neurol 405 
Neurosurg. 2018;173:163-168. 406 
28. Ilniczky S, Jelencsik I, Kenez J, Szirmai I. MR findings in subacute combined degeneration of 407 
the spinal cord caused by nitrous oxide anaesthesia--two cases. Eur J Neurol. 2002;9(1):101-408 
104. 409 
29. Committee JF. British National Formulary. In: London: Pharmaceutical Press; 2016. 410 
30. Giordano L, Akinyede O, Bhatt N, Dighe D, Iqbal A. Methotrexate-Induced Neurotoxicity in 411 
Hispanic Adolescents with High-Risk Acute Leukemia-A Case Series. J Adolesc Young Adult 412 
Oncol. 2017;6(3):494-498. 413 
31. Millan NC, Pastrana A, Guitter MR, Zubizarreta PA, Monges MS, Felice MS. Acute and sub-414 
acute neurological toxicity in children treated for acute lymphoblastic leukemia. Leuk Res. 415 
2018;65:86-93. 416 
32. Bond J, Hough R, Moppett J, Vora A, Mitchell C, Goulden N. 'Stroke-like syndrome' caused by 417 
intrathecal methotrexate in patients treated during the UKALL 2003 trial. Leukemia. 418 
2013;27(4):954-956. 419 
33. van der Plas E, Schachar RJ, Hitzler J, et al. Brain structure, working memory and response 420 
inhibition in childhood leukemia survivors. Brain Behav. 2017;7(2):e00621. 421 
34. Van Der Plas E, Erdman L, Nieman BJ, et al. Characterizing neurocognitive late effects in 422 
childhood leukemia survivors using a combination of neuropsychological and cognitive 423 
neuroscience measures. Child Neuropsychol. 2018;24(8):999-1014. 424 
35. Nassar SL, Conklin HM, Zhou Y, et al. Neurocognitive outcomes among children who 425 
experienced seizures during treatment for acute lymphoblastic leukemia. Pediatric blood & 426 
cancer. 2017;64(8). 427 
36. Mahoney DH, Jr., Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-428 
precursor acute lymphoid leukemia: an association with intermediate-dose intravenous 429 
methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. Journal of 430 
clinical oncology : official journal of the American Society of Clinical Oncology. 431 
1998;16(5):1712-1722. 432 
37. Gibson EM, Nagaraja S, Ocampo A, et al. Methotrexate Chemotherapy Induces Persistent 433 
Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment. Cell. 434 
2018. 435 
38. Li Y, Vijayanathan V, Gulinello M, Cole PD. Intrathecal methotrexate induces focal cognitive 436 
deficits and increases cerebrospinal fluid homocysteine. Pharmacol Biochem Behav. 437 
2010;95(4):428-433. 438 
39. Vijayanathan V, Gulinello M, Ali N, Cole PD. Persistent cognitive deficits, induced by 439 
intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic 440 
glutamate analogs and can be reversed by an NMDA antagonist. Behav Brain Res. 441 
2011;225(2):491-497. 442 
15 
 
40. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in 443 
children with leukemia. Journal of clinical oncology : official journal of the American Society 444 
of Clinical Oncology. 2003;21(16):3084-3091. 445 
41. Surtees R, Clelland J, Hann I. Demyelination and single-carbon transfer pathway metabolites 446 
during the treatment of acute lymphoblastic leukemia: CSF studies. Journal of clinical 447 
oncology : official journal of the American Society of Clinical Oncology. 1998;16(4):1505-448 
1511. 449 
42. Myles PS, Chan MT, Leslie K, Peyton P, Paech M, Forbes A. Effect of nitrous oxide on plasma 450 
homocysteine and folate in patients undergoing major surgery. Br J Anaesth. 451 
2008;100(6):780-786. 452 
43. Nagele P, Tallchief D, Blood J, Sharma A, Kharasch ED. Nitrous oxide anesthesia and plasma 453 
homocysteine in adolescents. Anesth Analg. 2011;113(4):843-848. 454 
44. Selzer RR, Rosenblatt DS, Laxova R, Hogan K. Adverse effect of nitrous oxide in a child with 455 
5,10-methylenetetrahydrofolate reductase deficiency. The New England journal of medicine. 456 
2003;349(1):45-50. 457 
45. McNeely JK, Buczulinski B, Rosner DR. Severe neurological impairment in an infant after 458 
nitrous oxide anesthesia. Anesthesiology. 2000;93(6):1549-1550. 459 
46. Pichardo D, Luginbuehl IA, Shakur Y, Wales PW, El-Sohemy A, O'Connor DL. Effect of nitrous 460 
oxide exposure during surgery on the homocysteine concentrations of children. 461 
Anesthesiology. 2012;117(1):15-21. 462 
47. Jain P, Gulati S, Toteja GS, Bakhshi S, Seth R, Pandey RM. Serum alpha tocopherol, vitamin 463 
B12, and folate levels in childhood acute lymphoblastic leukemia survivors with and without 464 
neuropathy. J Child Neurol. 2015;30(6):786-788. 465 
48. Goldhirsch A, Gelber RD, Tattersall MN, Rudenstam CM, Cavalli F. Methotrexate/nitrous-466 
oxide toxic interaction in perioperative chemotherapy for early breast cancer. Lancet. 467 
1987;2(8551):151. 468 
49. Goldhirsch A. Toxic effects of early adjuvant chemotherapy for breast cancer. Lancet. 469 
1983;2(8349):542-544. 470 
50. Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients 471 
aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606-615. 472 
51. Lassen HC, Kristensen HS. Remission in chronic myeloid leucaemia following prolonged 473 
nitrous oxide inhalation. Dan Med Bull. 1959;6:252-255. 474 
52. Ermens AA, Kroes AC, Schoester M, van Lom K, Lindemans J, Abels J. Effect of cobalamin 475 
inactivation on folate metabolism of leukemic cells. Leuk Res. 1988;12(11-12):905-910. 476 
53. Ermens AA, Schoester M, Spijkers LJ, Lindemans J, Abels J. Toxicity of methotrexate in rats 477 
preexposed to nitrous oxide. Cancer research. 1989;49(22):6337-6341. 478 
54. Kroes AC, Lindemans J, Schoester M, Abels J. Enhanced therapeutic effect of methotrexate in 479 
experimental rat leukemia after inactivation of cobalamin (vitamin B12) by nitrous oxide. 480 
Cancer chemotherapy and pharmacology. 1986;17(2):114-120. 481 
55. Chanarin I. The effects of nitrous oxide on cobalamins, folates, and on related events. Crit 482 
Rev Toxicol. 1982;10(3):179-213. 483 
56. Chanarin I, Deacon R, Lumb M, Muir M, Perry J. Cobalamin-folate interrelations: a critical 484 
review. Blood. 1985;66(3):479-489. 485 
57. Black KA, Tephly TR. Effects of nitrous oxide and methotrexate administration on hepatic 486 
methionine synthetase and dihydrofolate reductase activities, hepatic folates, and formate 487 
oxidation in rats. Mol Pharmacol. 1983;23(3):724-730. 488 
58. Kondo H, Osborne ML, Kolhouse JF, et al. Nitrous oxide has multiple deleterious effects on 489 
cobalamin metabolism and causes decreases in activities of both mammalian cobalamin-490 
dependent enzymes in rats. J Clin Invest. 1981;67(5):1270-1283. 491 
59. Resnik DB. The precautionary principle and medical decision making. J Med Philos. 492 
2004;29(3):281-299. 493 
16 
 
60. Banerjee P, Rossi MG, Anghelescu DL, et al. Association Between Anesthesia Exposure and 494 
Neurocognitive and Neuroimaging Outcomes in Long-term Survivors of Childhood Acute 495 
Lymphoblastic Leukemia. JAMA Oncol. 2019. Jun 20. doi: 10.1001/jamaoncol.2019.1094. 496 
[Epub ahead of print] 497 
 498 
FIGURE LEGENDS 499 
Figure 1. A summary of the biochemical reactions involving folate and vitamin B12 inside an 500 
oligodendrocyte and proposed inhibition of myelin production by co-administration of 501 
methotrexate (MTX) and N2O.  502 
MTHF participates in the production of methionine from homocysteine by methionine synthase, 503 
catalyzed by MB12and zinc, creating THF and methionine. THF participates in the production of 504 
purines and pyrimidines for DNA synthesis. Methionine is a vital amino acid involved in myelin 505 
production via its conversion to S-adenosyl methionine (SAM). SAM is involved in the methylation of 506 
many proteins and intermediates ultimately involved in myelin production, such as 507 
phosphatidylcholine, which is important in the production of sphingomyelin, a major component of the 508 
myelin sheath. Homocysteine can be converted to homocysteic acid and homocysteine sulfinic acid 509 
which are excitotoxic glutamate analogues acting at the N-methyl- d -aspartate (NMDA) receptor, 510 
which may be a factor in acute methotrexate-induced neurotoxicity. Methotrexate inhibits the function 511 
of DHFR, preventing the conversion of DHF to MTHF. Active vitamin B12contains reduced cobalt 512 
(Co+), but N2O produces irreversible oxidation to Co++ and Co+++, rendering vitamin B12 inactive. 513 
Any simultaneous compromise of folate and vitamin B12 via co-administration of methotrexate and 514 
N2O could result in increased homocysteine and reduced methionine levels both of which may 515 
contribute to the neurotoxic effects of methotrexate treatment. Arrows indicate proposed increase or 516 
reduction in various relevant pathway metabolites and processes due to methotrexate (orange) and 517 
N2O (blue), respectively. Adapted from Forster et al, 2016 (8). 518 
Abbreviations: 5-MTHF (5-methyltetrahydrofolate, levomefolic acid), MB12 (methyl B12), THF 519 
(tetrahydrofolate, tetrahydrofolic acid), 5,10-MTHF (5,10-methylene THF), DHF (dihydrofolate, 520 
dihydrofolic acid), DHFR (dihydrofolate reductase), MTHFR (methylenetetrafolate reductase), met 521 
synthase (methionine synthase), SHMT (serine hydroxyl-methyltransferase).  522 
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